These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 17929411)

  • 21. Laboratory investigation of immune responses to acellular pertussis vaccines when used for boosting adolescents after primary immunisation with whole cell pertussis vaccines: a comparison with data from clinical study.
    Reynolds E; Walker B; Xing D; Southern J; Asokanathan C; Dagg B; Corbel M; Miller E
    Vaccine; 2006 Apr; 24(16):3248-57. PubMed ID: 16480794
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antigenic variants in Bordetella pertussis strains isolated from vaccinated and unvaccinated children.
    Mastrantonio P; Spigaglia P; Oirschot HV; van der Heide HGJ; Heuvelman K; Stefanelli P; Mooi FR
    Microbiology (Reading); 1999 Aug; 145 ( Pt 8)():2069-2075. PubMed ID: 10463173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Genetic variability of Bordetella pertussis strains. Part II. Perspectives].
    Gzyl A; Augustynowicz E; Gniadek G; Slusarczyk J
    Przegl Epidemiol; 2003; 57(1):193-200. PubMed ID: 12926328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Investigation of the Cellular Immune Response to Recombinant Fragments of Filamentous Hemagglutinin and Pertactin of Bordetella pertussis in BALB/c Mice.
    Bakhshaei P; Kazemi MH; Golara M; Abdolmaleki S; Khosravi-Eghbal R; Khoshnoodi J; Judaki MA; Salimi V; Douraghi M; Jeddi-Tehrani M; Shokri F
    J Interferon Cytokine Res; 2018 Apr; 38(4):161-170. PubMed ID: 29638208
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of experimental and commercial pertussis vaccines in the elimination of Bordetella pertussis isolates with different genetic profiles in murine model.
    Prygiel M; Mosiej E; Wdowiak K; Górska P; Polak M; Lis K; Krysztopa-Grzybowska K; Zasada AA
    Med Microbiol Immunol; 2021 Dec; 210(5-6):251-262. PubMed ID: 34338880
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cell-mediated immunity after pertussis vaccination and after natural infection.
    Zepp F; Knuf M; Habermehl P; Schmitt HJ; Meyer C; Clemens R; Slaoui M
    Dev Biol Stand; 1997; 89():307-14. PubMed ID: 9272364
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lung pathology and immediate hypersensitivity in a mouse model after vaccination with pertussis vaccines and challenge with Bordetella pertussis.
    Vandebriel RJ; Gremmer ER; Vermeulen JP; Hellwig SM; Dormans JA; Roholl PJ; Mooi FR
    Vaccine; 2007 Mar; 25(12):2346-60. PubMed ID: 17224216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life.
    Guiso N; Njamkepo E; Vié le Sage F; Zepp F; Meyer CU; Abitbol V; Clyti N; Chevallier S
    Vaccine; 2007 Feb; 25(8):1390-7. PubMed ID: 17134795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The role of Toll-like receptor-4 in pertussis vaccine-induced immunity.
    Banus S; Stenger RM; Gremmer ER; Dormans JA; Mooi FR; Kimman TG; Vandebriel RJ
    BMC Immunol; 2008 May; 9():21. PubMed ID: 18498620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Granulocyte-macrophage colony-stimulating factor DNA prime-protein boost strategy to enhance efficacy of a recombinant pertussis DNA vaccine.
    Li QT; Zhu YZ; Chu JY; Dong K; He P; Feng CY; Hu BY; Zhang SM; Guo XK
    Acta Pharmacol Sin; 2006 Nov; 27(11):1487-94. PubMed ID: 17049126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults.
    He Q; Tran Minh NN; Edelman K; Viljanen MK; Arvilommi H; Mertsola J
    Infect Immun; 1998 Aug; 66(8):3796-801. PubMed ID: 9673264
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Molecular genetic characteristics of the B. pertussis strains isolated in different periods of the pertussis epidemic process].
    Mazurova IK; Borisova OIu; Kombarova SIu; Zakharova NS; Aleshkin VA
    Mol Gen Mikrobiol Virusol; 2005; (4):21-5. PubMed ID: 16334221
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutants of Escherichia coli heat-labile toxin act as effective mucosal adjuvants for nasal delivery of an acellular pertussis vaccine: differential effects of the nontoxic AB complex and enzyme activity on Th1 and Th2 cells.
    Ryan EJ; McNeela E; Murphy GA; Stewart H; O'hagan D; Pizza M; Rappuoli R; Mills KH
    Infect Immun; 1999 Dec; 67(12):6270-80. PubMed ID: 10569737
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interleukin-12 is produced by macrophages in response to live or killed Bordetella pertussis and enhances the efficacy of an acellular pertussis vaccine by promoting induction of Th1 cells.
    Mahon BP; Ryan MS; Griffin F; Mills KH
    Infect Immun; 1996 Dec; 64(12):5295-301. PubMed ID: 8945580
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Intranasal murine model of Bordetella pertussis infection: II. Sequence variation and protection induced by a tricomponent acellular vaccine.
    Boursaux-Eude C; Thiberge S; Carletti G; Guiso N
    Vaccine; 1999 Jun; 17(20-21):2651-60. PubMed ID: 10418915
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal and systemic immune responses elicited by recombinant Lactococcus lactis expressing a fusion protein composed of pertussis toxin and filamentous hemagglutinin from Bordetella pertussis.
    Torkashvand A; Bahrami F; Adib M; Ajdary S
    Microb Pathog; 2018 Jul; 120():155-160. PubMed ID: 29738814
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenicity and protective efficacy of neonatal vaccination against Bordetella pertussis in a murine model: evidence for early control of pertussis.
    Roduit C; Bozzotti P; Mielcarek N; Lambert PH; del Giudice G; Locht C; Siegrist CA
    Infect Immun; 2002 Jul; 70(7):3521-8. PubMed ID: 12065491
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge.
    Nascimento IP; Dias WO; Quintilio W; Christ AP; Moraes JF; Vancetto MD; Ribeiro-Dos-Santos G; Raw I; Leite LC
    Microbes Infect; 2008 Feb; 10(2):198-202. PubMed ID: 18248757
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of different forms of adenylate cyclase toxin of Bordetella pertussis on protection afforded by an acellular pertussis vaccine in a murine model.
    Cheung GY; Xing D; Prior S; Corbel MJ; Parton R; Coote JG
    Infect Immun; 2006 Dec; 74(12):6797-805. PubMed ID: 16982827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.